The deal isn’t done, but would be Merck’s biggest oncology buy.

Myelofibrosis projects and Merck's ROR1 ADC fight for attention at this month's conference.

First-in-human study starts include radioligands from Akiram and Philogen.

Prelude’s SMARCA2 project and C4’s BRAF hopeful look lacklustre.

ASP3082 grabs some early attention among degraders set to feature at ESMO.